P 1201
Alternative Names: P1201; P1201-07Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Developer Piramal Enterprises
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Metabolic-disorders in France
- 16 Jul 2016 No recent reports of development identified for phase-I development in Metabolic-disorders in Netherlands
- 29 Feb 2008 Phase-I clinical trials in Metabolic disorders in Netherlands (unspecified route)